Subscribe

0

DGCI

DRDO LimeLight

Anti-COVID Drug by DRDO Gets DCGI's Approval

In April 2020, during the first wave of the pandemic, INMAS-DRDO scientists conducted laboratory experiments with the help of Centre for Cellular and Molecular Biology (CCMB), Hyderabad and found that this molecule works effectively against SARS-CoV-2 virus and inhibits the viral growth. Based on these results, Drugs Controller General of India’s (DCGI) Central Drugs Standard Control Organization (CDSCO) permitted Phase-II clinical trial of 2-DG in COVID-19 patients in May 2020.

By SMEStreet Edit Desk
May 08, 2021 12:11 IST 3 Min read
Progress on COVID vaccine, SMESTreet News
DCGI Explained Emergency Approval of COVID-19 Virus Vaccine
By SMEStreet Edit Desk
Jan 04, 2021 04:34 IST 3 Min read
Dr Harsh Vardhan, COVID-19, WHO, COVID Testing News
DCGI Approves Phase II+III Trials of Oxford University Vaccine by Serum Institute
By SMEStreet Desk
Aug 03, 2020 11:11 IST 1 Min read
Glenn Saldahna, Stock Market, BSE, Glenmark Pharmaceuticals, USFDA, Acid Reflux News
Glenmark’s Favipiravir is Different from Livealth Bio Pharma’s Livfavir
By SMEStreet Desk
Jun 25, 2020 09:45 IST 2 Min read
dilip shanghvi, Sun Pharma, US FDA, Sectors
Sun Pharma's AQCH - Phytopharmaceutical Drug Goes into Phase 2 Clinical Trial for COVID-19 Treatment
By SMEStreet Desk
Jun 05, 2020 08:02 IST 2 Min read
dilip shanghvi, Sun Pharma, US FDA, News
Sun Pharma Gets DGCI's Approval for Nafamostat Mesilate Clinical Trials on COVID-19 Patients
By SMEStreet Desk
May 29, 2020 11:53 IST 2 Min read
Kiran Mazumdar Shaw, Biocon News
DGCI Approved Biocon's CytoSorb for COVID-19 Treatment
By SMEStreet Desk
May 27, 2020 09:04 IST 1 Min read